Business

Prudential Financial, Inc. announces 2020 results

Fourth quarter 2020 net income attributable to Prudential Financial, Inc. of $819 million or $2.03 per Common share versus $1.128 billion or $2.76 per share for the year-ago quarter. Fourth quarter 2020 after-tax adjusted operating income of $1.183 billion or $2.93 per

Business, Technology

John Sarkis joins Align as Chief Revenue Officer

NEW YORK — (BUSINESS WIRE) — #ITtransformation—Align, the premier global provider of technology infrastructure solutions and managed IT services, today announced the appointment of John Sarkis as Chief Revenue Officer. John brings 20+ years of experience leading high-performance business lines in various

Business, Technology

Wipro included in 2021 Bloomberg Gender-Equality Index

EAST BRUNSWICK, N.J. & BANGALORE, India — (BUSINESS WIRE) — #Bloomberg–Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced that it has been included in the 2021 Bloomberg Gender-Equality Index

Business, Technology

Catalent, Inc. reports second quarter fiscal 2021 results

Q2’21 net revenue of $910.8 million increased 26% as-reported, or 24% in constant currency, compared to Q2’20. Organic, constant currency net revenue grew 17%, compared to Q2’20. Q2’21 net earnings of $88.4 million increased 94%, or 88% in constant currency, compared to

Business, Healthcare, Science

Legend Biotech announces BCMA CAR-T Therapy Cilta-cel accepted for accelerated assessment in Europe for the treatment of relapsed and/or refractory multiple myeloma

SOMERSET, N.J. — (BUSINESS WIRE) — Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, announced today that the Committee for Medicinal Products for

Business, Healthcare

Merck presents results from head-to-head Phase 3 KEYNOTE-598 Trial evaluating KEYTRUDA® (pembrolizumab) in combination with ipilimumab versus KEYTRUDA Monotherapy in certain patients with metastatic non-small cell lung cancer

Findings Presented in World Conference on Lung Cancer 2020 Presidential Symposium and Published in the Journal of Clinical Oncology KENILWORTH, N.J. — (BUSINESS WIRE) — $MRK #MRK— Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced first-time data